e-learning
resources
ERJ
2013
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial
Hoeper Marius M., Halank Michael, Wilkens Heinrike, Günther Andreas, Weimann Gerrit, Gebert Irmingard, Leuchte Hanno H., Behr Jürgen
Source:
Eur Respir J 2013; 41: 853-860
Journal Issue:
April
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Hoeper Marius M., Halank Michael, Wilkens Heinrike, Günther Andreas, Weimann Gerrit, Gebert Irmingard, Leuchte Hanno H., Behr Jürgen. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J 2013; 41: 853-860
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
Source: Eur Respir Rev 2009; 19: 68-71
Year: 2010
Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy
Source: Eur Respir Rev 2009; 18: 35-41
Year: 2009
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension
Source: Eur Respir J 2009; 33: 785-792
Year: 2009
Baseline characteristics and survival of patients with pulmonary hypertension in interstitial lung disease in the “HYPID” study
Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology
Year: 2013
Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study
Source: Annual Congress 2013 –Pulmonary circulation: treatment
Year: 2013
RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors
Source: International Congress 2016 – Clinic of pulmonary hypertension
Year: 2016
Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial
Source: Eur Respir J 2006; 27: 972-979
Year: 2006
Comparison of pulmonary hypertension (PH) associated to chronic lung disease to other PH groups
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Pulmonary hypertension: future therapies
Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=84
Year: 2004
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Sildenafil is a potent pulmonary vasodilator in pulmonary hypertension associated with interstitial lung disease: impact on gas exchange properties
Source: Eur Respir J 2002; 20: Suppl. 38, 598s
Year: 2002
Pulmonary hypertension in interstitial lung disease
Source: Eur Respir J 2008; 31: 1357-1367
Year: 2008
Effect of PDE-5 inhibitor treatment in patients with interstitial lung disease and pulmonary hypertension
Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Year: 2011
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i)
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
Source: Eur Respir J 2005; 26: 586-593
Year: 2005
Tyrosine kinase inhibition in pulmonary hypertension: the anti-proliferative approach
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease
Source: Annual Congress 2012 - Sarcoidosis
Year: 2012
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension
Source: Eur Respir J 2008; 32: 881-891
Year: 2008
Pulmonary hypertension in patients with interstitial lung disease
Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept